•  

    EXELTIS

    We develop innovative treatments that contribute to meet unmet medical needs on the five continents.

     

  •  

    EXELTIS

    We develop innovative treatments that contribute to meet unmet medical needs on the five continents.

     

  •  

    EXELTIS

    We develop innovative treatments that contribute to meet unmet medical needs on the five continents.

     

  •  

    EXELTIS

    We develop innovative treatments that contribute to meet unmet medical needs on the five continents.

     

Solutions for people’s wellbeing and health

Exeltis is an organization focused on developing, producing and facilitating treatment for millions of people around the world. It has a presence in more than 40 countries, 4,000 employees, more than 30 affiliates around the world, and a global manufacturing network in Europe, Americas and Asia.

The goals of Exeltis R&D are to facilitate better and effective therapeutic solutions for patients -particularly women- and doctors, to extend therapeutic options for the treatment of various diseases and to meet unmet health needs.

In Argentina, Exeltis is present through Laboratorio Elea. With more than 75 years of experience, Elea researches and develops reliable medicines for a range of medicinal specialties.

It is one of the top pharmaceutical companies of Argentina in terms of revenues. It has leading brands, innovative R&D projects, and licenses from major international companies. With its own production plants and a wide distribution network, it is oriented to the development of new products, mainly in the areas of Women’s Health, Cardiology, Neurosciences, Oncology and OTC drugs.

+ Read more

News Exeltis

(Español) 31 de agosto de 2017

Estados Unidos aprueba el benznidazol para el tratamiento de niños con la enfermedad de Chagas

Washington D.C./Buenos Aires/Madrid/Ginebra – 31 de agosto de 2017 La Fundación Mundo Sano, Grupo Insud y Laboratorios Elea tienen el orgullo de comunicar que, el 29 de agosto, la Administración de Alimentos y Fármacos de los Estados Unidos (FDA, por … Continue reading

+
(Español) Exeltis, de Grupo Insud, adquiere una división del laboratorio Juste de España Apertura

Exeltis, more leader than ever in Spain

This is Exeltis from the Insud Group which recently acquired the Juste Farma division of the Juste laboratory in Spain. This long-standing company is dedicated to the sale of pharmaceutical products of gynecology, central nervous system and primary care. Beyond … Continue reading

+